Diagonal Bio announces successful pilot study results and extended partnership with Hørsholm Veterinary Clinic
Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces the extension of its partnership with Hørsholm Veterinary Clinic following the successful completion of a three-month pilot study. The pilot study was focused on utilizing Diagonal Bio’s platform technology, LAMPlify®, for the detection of viral infections in horses. The successful results were validated by an independent external laboratory in Germany, underscoring the efficacy and reliability of the LAMPlify® analysis system.
The pilot study tested Diagonal Bio’s LAMPlify® technology on a series of samples from horses suspected of carrying respiratory viruses. The tests confirmed the presence of virus infections in several of the horses tested. The pilot study not only demonstrated LAMPlify®’s capability to accurately identify viral infections but also proved that it is a valuable tool in the early detection of such diseases, thereby enabling timely intervention and treatment.
Following the pilot study’s success, Diagonal Bio and Hørsholm Veterinary Clinic have agreed to continue their partnership, which was initiated last fall and communicated on November 27, 2023. Hørsholm Veterinary Clinic will continue to use the LAMPlify® system for testing viral infections in horses and harness the potential of the LAMPlify® technology in enhancing horse health and welfare.
“Our objective is that all new incoming horses to a stable or a race should be tested with LAMPlify® to minimize the spread of respiratory viruses and to avoid costly isolation of horses. The success of this pilot study with Diagonal Bio’s technology has set a new standard in veterinary diagnostics, and we are looking forward to continuing our partnership.” - Daniel Taasti Melgaard, Veterinary and Partner at Hørsholm Veterinary Clinic.
“This step marks a significant milestone for Diagonal Bio as we continue to push the boundaries of diagnostic technologies. The validation of our LAMPlify® technology not only reinforces our commitment to excellence but also demonstrates our capability to make a real impact in the field of veterinary medicine. We are excited about the prospects of our continued collaboration with Hørsholm Veterinary Clinic and the positive implications it holds for animal healthcare. Diagonal Bio remains dedicated to developing and providing advanced diagnostic solutions that contribute to the health and well-being of animals.” - Karin Wehlin, CEO of Diagonal Bio AB (publ).
For more information about the Company, please contact:
Karin Wehlin, CEO
Phone: +46 (0)70 305 24 88
E-mail: [email protected]
www.diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: [email protected]
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on April 05, 2024, at 15:00 CET.
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.
